Accelerating medical breakthroughs through rigorous, transparent, and patient-centric clinical research across multiple therapeutic areas.
Multicenter, randomized, double-blind trial assessing efficacy and safety of oral ZN-789 monotherapy versus standard chemotherapy in stage IV non-small cell lung cancer.
Global Phase III program evaluating cognitive preservation and biomarker modulation in mild-to-moderate Alzheimer's disease over a 18-month treatment period.
Open-label, dose-escalation study to determine maximum tolerated dose, pharmacokinetics, and preliminary anti-inflammatory activity in healthy volunteers and RA patients.
Event-driven trial assessing reduction in major adverse cardiovascular events (MACE) with novel lipid-modulating therapy following acute myocardial infarction.
Real-world evidence study tracking long-term safety, treatment adherence, and quality-of-life metrics across 900+ sites following FDA approval.
Randomized controlled trial evaluating AI-driven neurofeedback and CBT integration in adults with TRD, measuring PHQ-9 scores and neural connectivity markers.
Safety & Dosing
Efficacy & Biomarkers
Global Multicenter
Real-World Evidence
Published Results
Across 58 Nations
Every Zenth Health Sciences trial adheres to ICH-GCP guidelines, FDA/EMA regulations, and WHO standards. Our Independent Ethics Committees (IECs) and Data Safety Monitoring Boards (DSMBs) operate autonomously to ensure patient welfare remains the highest priority. All protocols are registered publicly on ClinicalTrials.gov and EU Clinical Trials Register.
Partner with Zenth Health Sciences to accelerate clinical research, join our investigator network, or explore sponsored trial opportunities.